RxDoctor Payments Data

Patrick Fenlon

Internal Medicine · Thomasville, GANPI 1841259934

Payments from drug & device makers

$1,528in general payments, 2019–2025

Across 92 payments — averaging $16.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$304
  • Amgen$155
  • Johnson & Johnson$146
  • AstraZeneca$136
  • Boehringer Ingelheim$113
  • AbbVie$92
  • plus $582 from 17 others

What the payments were for

  • Food & beverage$1,528100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,528 in reported general payments places this provider in the 70th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$2,630
Medicare patients
24
Services billed
39

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab17$12,947
OzempicSemaglutide11$12,711
FarxigaDapagliflozin Propanediol12$7,012
Pantoprazole Sodium37$747
Nebivolol Hcl16$525
Atorvastatin Calcium43$501
Losartan Potassium64$472
Rosuvastatin Calcium46$432
Zolpidem Tartrate41$332
Famotidine15$291
Pregabalin19$289
Metoprolol Succinate18$262
Levothyroxine Sodium19$252
Potassium Citrate ErPotassium Citrate12$183
Atenolol11$165

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$304$12,71111 claims
AstraZenecaFarxiga$136$7,01212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Thomasville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →